Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AIM ImmunoTech Inc (AIM)
NYSE MKT:AIM
AIM ImmunoTech (AIM) Stock Price & Analysis
826 Followers
AIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.31 - $0.72
Previous Close$0.36
Volume168.19K
Average Volume (3M)264.25K
Market Cap
$20.85M
Enterprise Value-$831.83K
Total Cash (Recent Filing)$22.43M
Total Debt (Recent Filing)$750.00K
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 13, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding51,281,437
10 Day Avg. Volume304,733
30 Day Avg. Volume264,247
Standard Deviation0.28
R-Squared0.00467
Alpha-0.00358
Financial Highlights & Ratios
Price to Book (P/B)11.54
Price to Sales (P/S)149.26
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.29
Enterprise Value/Gross Profit-5.90
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$3.50Price Target Upside859.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
AIM ImmunoTech News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has 12 active clinical trials in progress.
Drug Approval And ApplicationsAmpligen is approved in Argentina for the treatment of severe chronic fatigue syndrome and is being evaluated for post-COVID-19 conditions.
Financial PerformanceThe company has $13 million in cash and no debt.
Bears Say
Cash PositionAIM ended 1Q24 with only $10.9 million in cash, which may limit its financial flexibility moving forward.
EarningsAIM reported a net loss of $12.5 million in 4Q23, which raises concerns about the company's profitability.
Financial PerformanceAIM reported a net loss of $5.8 million in 1Q24, indicating ongoing financial struggles.
---
Ownership Overview
7.14% Insiders
4.20% Mutual Funds
3.52% Other Institutional Investors
85.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AIM FAQ
What was AIM ImmunoTech Inc’s price range in the past 12 months?
AIM ImmunoTech Inc lowest stock price was $0.30 and its highest was $0.72 in the past 12 months.
What is AIM ImmunoTech Inc’s market cap?
Currently, no data Available
When is AIM ImmunoTech Inc’s upcoming earnings report date?
AIM ImmunoTech Inc’s upcoming earnings report date is Aug 13, 2024 which is in 16 days.
How were AIM ImmunoTech Inc’s earnings last quarter?
Currently, no data Available
Is AIM ImmunoTech Inc overvalued?
According to Wall Street analysts AIM ImmunoTech Inc’s price is currently Undervalued.
Does AIM ImmunoTech Inc pay dividends?
AIM ImmunoTech Inc does not currently pay dividends.
What is AIM ImmunoTech Inc’s EPS estimate?
AIM ImmunoTech Inc’s EPS estimate is -$0.12.
How many shares outstanding does AIM ImmunoTech Inc have?
AIM ImmunoTech Inc has 57,136,680 shares outstanding.
What happened to AIM ImmunoTech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AIM ImmunoTech Inc?
Currently, no hedge funds are holding shares in AIM
---
AIM ImmunoTech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (859.17% Upside)
$3.50 (859.17% Upside)
Insider Transactions
Bought Shares
Worth $37.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.47%
12-Months-Change
Fundamentals
Return on Equity
-156.31%
Trailing 12-Months
Asset Growth
-56.79%
Trailing 12-Months
Company Description
AIM ImmunoTech Inc
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
---
AIM Earnings Call
Q1 2024
0:00 / 0:00
---
AIM Stock 12 Month Forecast
Average Price Target
$3.50
▲(859.17% Upside)
Technical Analysis
Best Analysts Covering AIM
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-14.67%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -14.67% per trade.
---